Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 645.05 INR
Change Today +2.95 / 0.46%
Volume 4.5K
IPCA On Other Exchanges
Symbol
Exchange
Natl India
As of 11:59 PM 05/3/15 All times are local (Market data is delayed by at least 15 minutes).

ipca laboratories ltd (IPCA) Snapshot

Open
644.40
Previous Close
642.10
Day High
646.90
Day Low
641.20
52 Week High
06/30/14 - 899.30
52 Week Low
02/9/15 - 591.25
Market Cap
81.4B
Average Volume 10 Days
192.9K
EPS TTM
37.92
Shares Outstanding
126.2M
EX-Date
07/18/14
P/E TM
17.0x
Dividend
2.50
Dividend Yield
0.78%
Current Stock Chart for IPCA LABORATORIES LTD (IPCA)

Related News

No related news articles were found.

ipca laboratories ltd (IPCA) Related Businessweek News

No Related Businessweek News Found

ipca laboratories ltd (IPCA) Details

Ipca Laboratories Limited manufactures and supplies pharmaceutical formulations and active pharmaceutical ingredients for various therapeutic segments in India. It offers branded and generic formulations in various dosage forms, including oral solids and liquids, dry powders for suspension, and liquid and dry injectables. The company provides formulations for various therapeutic areas, such as cardiovascular, anti-diabetic, cardio-diabetic, rheumatology, orthopaedics, dermatology, gastro-intestinal, anti-bacterial, pain and hypertension management, respiratory, urology, nutraceutical, neuropsychiatry, anti-malarial, anti-infective, cough, geriatric, and non steroid anti-inflammatory drugs, as well as oral and injectable antibiotics for surgical and non-surgical needs. It also offers drug intermediates. The company also exports its products to approximately 130 countries worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

5,051 Employees
Last Reported Date: 05/30/09
Founded in 1949

ipca laboratories ltd (IPCA) Top Compensated Officers

Chairman, Chief Executive Officer, Managing D...
Total Annual Compensation: 30.0M
President of Apis & Generics and Executive Di...
Total Annual Compensation: 4.1M
Joint Managing Director, Executive Director a...
Total Annual Compensation: 6.0M
Executive Director and Member of Audit Commit...
Total Annual Compensation: 3.5M
Compensation as of Fiscal Year 2014.

ipca laboratories ltd (IPCA) Key Developments

Ipca Laboratories Limited, Board Meeting, Feb 13, 2015

Ipca Laboratories Limited, Board Meeting, Feb 13, 2015. Agenda: To consider subscription of equity shares.

Ipca Laboratories Limited, Q3 2015 Earnings Call, Feb 09, 2015

Ipca Laboratories Limited, Q3 2015 Earnings Call, Feb 09, 2015

Ipca Laboratories Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Ipca Laboratories Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, net sales/income from operation was INR 7,341.3 million against INR 8,219.9 million a year ago. Profit from operation before other income, foreign exchange transactions loss, finance cost and exceptional item was INR 791.5 million against INR 1,917.6 million a year ago. Profit from ordinary activities before tax was INR 685.5 million against INR 1,893.2 million a year ago. Net profit was INR 415.3 million or INR 3.29 per basic and diluted share against INR 1,391.2 million or INR 11.02 per basic and diluted share a year ago. EBITDA was INR 1,211.4 million against INR 2,173.4 million a year ago. EBITDA margin was 16.36% compared to 26.09% a year ago. For the nine months, net sales/income from operation was INR 24,372.0 million against INR 24,562.3 million a year ago. Profit from operation before other income, foreign exchange transactions loss, finance cost and exceptional item was INR 3,673.2 million against INR 5,479.8 million a year ago. Profit from ordinary activities before tax was INR 3,531.6 million against INR 4,545.9 million a year ago. Net profit was INR 2,483.2 million or INR 19.68 per basic and diluted share against INR 3,403.4 million or INR 26.97 per basic and diluted share a year ago. EBITDA was INR 4,868.3 million against INR 6,228.9 million a year ago. EBITDA margin was 19.81% compared to 25.06% a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPCA:IN 645.05 INR +2.95

IPCA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,720 INR +18.10
Cipla Ltd/India 646.65 INR +10.65
Dr Reddy's Laboratories Ltd 3,356 INR +45.60
Torrent Pharmaceuticals Ltd 1,208 INR +6.05
Wockhardt Ltd 1,316 INR +28.10
View Industry Companies
 

Industry Analysis

IPCA

Industry Average

Valuation IPCA Industry Range
Price/Earnings 10.7x
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 8.8x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPCA LABORATORIES LTD, please visit www.ipcalabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.